Agenus Inc.
https://agenusbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Agenus Inc.
Finance Watch: Earnings Season Brings Job Cuts, Even At Big Pharma
Restructuring Edition: Even big pharma companies are not immune from workforce reductions. BMS and Sanofi joined that ranks of Evotec, CureVac and BenevolentAI in cutting jobs. Also, Vaxxinity will de-list and Hepion winds down its NASH trial, among other strategic updates.
Lilly Mounjaro, Zepbound Supply Issues Persist Amid Strong Growth
Mounjaro revenue declined versus Q4 2023, Lilly reported, though grew 218% year-over-year. The pharma pledged significant ramp-up of manufacturing this year.
Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara
Public Company Edition: Cullinan and Cidara shifted their strategic directions and found investors to bring along for the ride. Also, Intra-Cellular closed a post-Phase III $575m follow-on offering and Tarsus accessed up to $200m from Pharmakon.
Analysis: Novo And Lilly Make Their Money Work
Pharma groups must decide how best to invest their cash to generate the biggest returns, and while huge sums can be made with luck and good judgement, strategic missteps can have far-reaching consequences.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Antigenics Inc. Aronex Pharmaceuticals AgenTus Therapeutics, Inc. Agenus Royalty Fund, LLC Agenus Switzerland Inc. Agenus UK Limited 4-Antibody
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice